Amplica Bio, Inc. — SEC Form D Filing

Amplica Bio, Inc. filed an SEC Form D on September 11, 2026, reporting $30K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 11, 2026
Amount reported
$30K
Round stage
Series B+
Industry
Biotechnology
Website
https://amplificabio.com/

What the company does

Securities: Equity, Simple Agreement for Future Equity (SAFE). Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Millions of men and women suffer from hair loss, specifically androgenic alopecia, and there is a significant unmet need for safe and effective products that can promote new hair growth.

Solution

Amplifica is developing novel treatments, including unique signaling molecules and a lead compound AMP-303, to stimulate hair follicles to regrow hair.

Why now

Advances in understanding hair biology and signaling pathways, coupled with a persistent market demand for effective hair regrowth solutions, create an opportune moment for novel biopharmaceutical treatments.

Verdict

This cleared because the biological mechanism promised a novel, durable solution to a widespread, well-understood condition, not because of demonstrated clinical efficacy or market traction. Investors were implicitly betting on the company's ability to navigate preclinical and early clinical development with a clear biological premise, targeting a consumer-driven market with high willingness to pay. However, the early-stage nature and reliance on a single lead compound limited upside, as success was entirely dependent on a protracted, capital-intensive R&D pipeline rather than rapid market penetration.

Source: SEC EDGAR Form D filing